Perrigo Company plc (PRGO) has received final approval from the U.S. Food & Drug Administration or FDA for its abbreviated new drug application or ANDA for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets and has commenced shipment of product. Earlier, Perrigo launched the 0.5 mg strength in 2013.
Prandin tablets, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of some $250 million, as measured by Symphony Health Solutions.
For comments and feedback: editorial@rttnews.com